A Randomized, Double-Blind, Placebo Controlled, 3-period, Proof of Mechanism, Cross-Over Study of Roflumilast Administered up to Steady State to Evaluate the Effects of Add-on Roflumilast to Second Generation Antipsychotics on Cognitive Impairment as Well as Brain Imaging (ie, fMRI) and Electrical Activity (ie, EEG) Changes Observed in Subjects With Stable Schizophrenia

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, 3-period, Proof of Mechanism, Cross-Over Study of Roflumilast Administered up to Steady State to Evaluate the Effects of Add-on Roflumilast to Second Generation Antipsychotics on Cognitive Impairment as Well as Brain Imaging (ie, fMRI) and Electrical Activity (ie, EEG) Changes Observed in Subjects With Stable Schizophrenia

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2016

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 16 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 04 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov
    • 04 May 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top